NEW YORK and SAN DIEGO, April 20, 2009 /PRNewswire-FirstCall/ — Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced today that Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will be shipped to wholesalers on April 24th and will be available at pharmacies beginning on April 28th. After Savella was approved by the U.S. Food and Drug Administration (FDA) on January 14, 2009, the companies submitted a minor post-approval cosmetic formulation change to the FDA which now has been approved.
Continue reading the story here.
I am hoping that this is not going to be another let down for me….lyrica and cymbalta did nothing at all for me.
Retirement is in the air for me. I can not do my job any longer and they are offering an early out.
Am looking forward to doing some volunteer work?
Trying to stay positive.